Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin + Insulin in Japanese T1DM (DEPICT-5)
NCT02582814Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin in type 1 diabetes mellitus (T1D) (2 arms), sponsored by AstraZeneca. Primary endpoints: Overall Adverse Event Summary at 52 weeks, Hypoglycemia at 52 weeks and 5 more. Started Oct 2015; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02582814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582814.